This approach could have great value in clinical settings, where liquid biopsies are now starting to be included in the validated tests panel used to detect mutations for target therapies, such as the use of alpelisib for the treatment of patients with hormone receptor-positive, HER2-negative, and PIK3CA-mutated advanced or metastatic BC progressed after previous endocrine therapy as monotherapy [36]. This evidence concerns the gene NR4A1 and breast cancer.